Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02711592 · ClinicalTrials.gov registry record · NA
Pharmacogenomics Information in Enhancing Post-operative Total Joint Replacement Pain Management: a Pilot Study
A NA study, sponsored by TriHealth.
- Terminated
- Registry status
- NA
- Development phase
- 4
- Enrollment target
NCT02711592: Clinical Trial NA study, sponsored by TriHealth.
NCT02711592 is a NA study that was terminated before completion, run by TriHealth. The registered enrollment target is 4 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02711592, a NA study, was terminated before completion, sponsored by TriHealth.
- TERMINATED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
Study Summary
The objective of this study is to see how pain management and its outcomes are effected when pharmacogenomic testing is used to determine patient specific pain medication and dosing. Our goal is to determine if through the use of analgesic genetic testing, TKA post-operative patients will see a decrease in narcotic consumption, postsurgical opioid- related adverse reactions, and length of stay, overall NRS pain scores and while maintaining or improving their satisfaction scores.
Primary Outcome
Numerical patient reported pain scales.
Interventions
- GENETIC Genetic Panel for Analgesics
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2016-10-05 |
| Est. Completion | 2019-08-22 |
| Phase | NA |
Why NCT02711592 stopped before completion
NCT02711592 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Genetic Panel for Analgesics is the first listed.
NCT02711592 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02711592 about?
NCT02711592 is a clinical study titled "Pharmacogenomics Information in Enhancing Post-operative Total Joint Replacement Pain Management: a Pilot Study". The objective of this study is to see how pain management and its outcomes are effected when pharmacogenomic testing is used to determine patient specific pain medication and dosing. Our goal is to determine if through the use of analgesic genetic testing, TKA post-operative patients will see a decr...
What is the current status of trial NCT02711592?
This trial is currently terminated. It is a NA study. The enrollment target is 4 participants. The study started on 2016-10-05. Estimated completion is 2019-08-22.
What interventions are being tested in trial NCT02711592?
The interventions under investigation include: Genetic Panel for Analgesics (GENETIC).
Who is sponsoring clinical trial NCT02711592?
This trial is sponsored by TriHealth, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02711592's enrollment target sits among peer trials
4 1996th of 2000 higher than 5 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI